| EMAIL: |
| PERSONAL WEBSITE: |
| PUBLICATIONS: |
I focus on the care of adult patients with blood cancers. I have led multiple national first in human, phase 1 and later stage trials including but not limited to blood cancers and cellular therapies including CAR-T, Cord Blood, and haploidentical transplantation. I am a member of the Combined International Bone Marrow Transplant Registry Lymphoma Writing Committee and the SWOG Leukemia Committees. I serve as chair or co-chair of multiple lymphoma/ leukemia trials, the most recent being the last national studies for Burkitt’s lymphoma, as well as the recent AML intergroup study, and national chair for the NK cell infusion study for AML. I have led our team’s novel approaches for the care of patients using non-myeloablative allogeneic therapy using haplo-identical, as well as matched donors. I have also led the first in human studies targeting acute myelogenous leukemia by linking diphtheria to a small molecule targeting the IL-3 receptor (now approved for BPDCN). I serve on various NIH/NHLBI grant review committees and am a member of ASH, ASCO, AACR, ASBMT, ASCI, and various ASH sub-committees. I proud to work with my many colleagues as I oversee the development and conduct of the Novant Health Cancer Institute. In recognition of this leadership and success in our clinical research efforts, I was fortunate to receive the NIH ‘Clinical Investigator Team Leadership Award’ in 2010.
|
NOVANT HEALTH MARKET(S): NOVANT HEALTH INSTITUTE(S): |
CLINICAL/RESEARCH INTERESTS:
Cancer, Cancer Biology, Clinical Trials, Drug Discovery, Genomics, Hematology |